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A perspective on targeting inflammation and cytokine actions in atherosclerosis 
 
• Abstract:  
Atherosclerosis, a chronic inflammatory disorder of the vasculature that results in 
cardiovascular disease, continues to pose a significant health and economic burden on modern 
society. Whilst inflammation has generally been accepted as the key driver of all stages in the 
disease, it was not until recently that inhibition of a specific pro-inflammatory cytokine 
(interleukin-1β) yielded successful results in the Canakinumab Anti-Inflammatory Thrombosis 
Outcomes Study (CANTOS) trial. This article offers a perspective on targeting inflammation 
for atherosclerosis, focusing on results of recent phase 3 clinical trials, and discusses other 
potential candidates together with future challenges and prospects. 
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Cardiovascular disease (CVD) is currently responsible for more than a quarter of global 
mortalities, with around 7.4 million people living with the condition in the UK alone (according 
to British Heart Foundation statistics (2019)). The rising worldwide prevalence is attributed to 
increasing diabetes and obesity, coinciding with widespread adaptation of a ‘westernized’ 
lifestyle, and continues to pose a significant health and socioeconomic burden on modern 
society. The prevailing challenge of reversing the consequences of increasingly high-risk, 
sedentary lifestyles and maintaining cardiovascular health has been a fundamental incentive 
for much of previous and current research, as well as healthcare initiatives. CVD, which 
includes myocardial infarction (MI), coronary heart disease (CHD), angina pectoris and 
cerebrovascular accidents (stroke), is often the end consequence of atherosclerosis; a chronic 
inflammatory disorder of the vasculature. For over 50 years, atherosclerosis has remained the 
top cause of morbidity and mortality in Western civilization and is currently the number one 
cause of deaths globally [1]. Despite clinical advancements over the last few decades that have 
positively influenced patient prognosis, the significant and persisting residual risk of recurrent 
adverse events has fueled the need for alternative approaches in cardiovascular medicine. 
 
2. Atherogenesis and disease progression 
 
Atherosclerosis is characterized by the formation of fibrous plaques within the walls of medium 
and large arteries. Sites of bifurcations and inner curvatures, which have been shown to be 
associated with persistent low-grade inflammation [2], are particularly susceptible to 
atherosclerosis initiation. Atherosclerotic plaques, or atheromas, are derived mainly from 
cholesterol deposition and accumulation within the subendothelial space, resulting in enhanced 
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occlusion and compromised cardiovascular function (illustrated in Figure 1 and described in 
more depth by [3-5]). Key factors of the disease, hyperlipidemia, oxidative stress and 
inflammation, are inextricably linked and collectively orchestrate pro-atherogenic processes 
that contribute to the increasingly dysfunctional phenotype. Endothelial dysfunction is the key 
initiating step of atherogenesis, with plaque development involving the formation of lipid-rich 
foam cells within the arterial intima and vascular smooth muscle cell (SMC; VSMC) 
proliferation and migration (see Figure 1). Elevated circulating low-density lipoprotein (LDL) 
cholesterol (LDL-C) is a key risk factor of atherogenesis, as these particles may infiltrate and 
accumulate within the vessel wall, where, locally-produced reactive oxygen species (ROS) 
induce their modification into oxidized LDL (oxLDL) [6]. Therefore, LDL-C has widely been 
used as a major marker and predictor of CVD risk [7]. 
 
Previously, it was widely believed that LDL infiltrates the endothelial barrier via passive 
diffusion; however, recent advancements suggest that scavenger receptor (SR) class B type 1 
(SR-B1) facilitates the delivery of LDL into the artery wall [8]. The oxLDL then triggers an 
immune response and activation of the surrounding endothelial cells (ECs). This results in the 
recruitment and migration of circulating monocytes and T-lymphocytes to the site of LDL 
accumulation. The oxLDL may also encourage necroptosis (a recently discovered, non-
apoptotic programmed cell death pathway) which induces morphologic changes to cells similar 
to that of necrosis, and inflammation within the surrounding tissues [9]. The recruited 
monocytes differentiate into macrophages under the influence of macrophage-colony 
stimulating factor (M-CSF) and excessively take up oxLDL, which is facilitated by SRs (e.g. 
CD36 and SR-A1) [10], to become lipid-laden foam cells; a hallmark of atherosclerosis 
(dysregulated lipid homeostasis in atherosclerosis is described in detail by [4]). Macrophages 
possess a high level of heterogeneity and plasticity, and are recognized to be fundamental 
instigators and drivers of atherosclerosis [11]. Although macrophages are beneficial and 
necessary for clearing the accumulated LDL initially, these cells can undergo metabolic 
reprogramming encouraged by different stresses within the atherosclerotic microenvironment 
[11]. This includes macrophage proliferation [12] and the production of inflammatory 
mediators that enhances pro-inflammatory/atherogenic processes. The resulting macrophage 
inflammation drives lesion formation and atherosclerosis development. Whilst macrophages 
were previously thought to be main precursors of foam cells in atherosclerotic lesions, 
advances in lineage-tracing techniques have recently shown VSMCs to also be a key cell type 
present in all stages of atherosclerosis, with the ability to adopt a range of phenotypes that 
resembles foam cells, macrophages and others [1]. VSMCs are therefore now also regarded as 
key contributors of foam cell formation [13], possessing a greater phenotypic plasticity than 
was previously acknowledged [1]. 
 
Death of the foam cells via apoptosis, necrosis and necroptosis (which stimulates additional 
infiltration of monocytes) [9], leads to the accumulation of cholesterol, apoptotic cells and 
cellular debris, leading to the formation of a lipid-rich necrotic core. The growth of this necrotic 
core, furthered by continued cell death and defective efferocytosis, exacerbates the 
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inflammatory burden with the release of a plethora of pro-inflammatory cytokines. Plaque 
progression involves the formation of a fibrous cap that encloses the plaque, and coincides with 
the infiltration of additional VSMCs from the tunica media to the intima, as they undergo 
phenotypic shift from a quiescent to a synthetic state (reviewed extensively by [1]). In the later 
stages, this plaque-stabilizing fibrous cap is broken down by the activity of matrix 
metalloproteinases (MMPs) (produced mainly by lesional macrophages), resulting in plaque 
destabilization and subsequent rupture. Vulnerable plaques tend to consist of a large lipid-rich 
necrotic core with a thin, unstable and highly-inflamed fibrous cap abundant in monocytes, 
macrophages and T-lymphocytes [10]. The consequence of plaque rupture is thrombosis that, 
depending on the anatomical location of the thrombus within the vascular bed, can manifest as 




3. Current pharmacological interventions 
 
 3.1 Statins: Blockbuster drugs with issues 
 
The primary intervention for atherosclerosis and CVD patients is lifestyle modifications to 
increase physical activity and reduce dietary lipid consumption, combined with therapeutic 
strategies that interfere with cholesterol metabolism to counteract hyperlipidemia. Currently, 
standard pharmacological agents mainly aim to reduce circulating LDL-C levels. Statins, 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, remain the first 
choice, cornerstone pharmaceutical intervention for the prevention of primary and secondary 
major adverse cardiovascular events (MACE). Statins reduce endogenous cholesterol synthesis 
[14] and increase hepatocyte LDL receptor (LDLR) expression to reduce plasma LDL-C [10]. 
Although statins reportedly produce a 22% risk reduction in cardiovascular events for every 
mmol/L reduction in LDL-C [15-17] and hence are effective and successful drugs, many 
patients on statin therapy fail to achieve target cholesterol levels despite maximal dosage [18-
20]. Other issues of statin therapy include tolerability and adverse side effects [21], contributing 
to non-compliance and subsequent uncontrolled LDL-C levels and residual risk. Clinical trials 
have identified significant residual cardiovascular risk in statin-treated patients, despite 
successful lowering of plasma cholesterol levels [22-24]. This is despite the additional anti-
inflammatory and other pleiotropic actions of statins [25]. Therefore, it is often difficult to 
gauge whether the protective actions of statins are due to its LDL-C-lowering ability, anti-
inflammatory activity, or a combination of both. 
 
 3.2 Other strategies targeting LDL-C 
 
Other lipoprotein-lowering interventions include monoclonal antibodies targeting proprotein 
convertase subtilisin/kexin type-9 (PCSK9), evolocumab and alirocumab, which prevent 
PCSK9-mediated degradation of the LDLR and thereby encourage liver LDL-C absorption 
[26]. Both antibodies have been shown to reduce LDL-C by over 50% in two phase 3 clinical 
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trials [27]. Key issues are, however, their high expense and questionable cost-effectiveness as 
regular subcutaneous injection is required. Thus, despite demonstrating significant CVD 
benefit in the large FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 
Inhibition in Patients With Elevated Risk) involving 27,564 patients [28], the cost restricts their 
application in clinical practice. Other strategies for PCSK9 inhibition include gene silencing 
via small interfering RNA (siRNA) to target the translation stage of PCSK9 synthesis [29]. 
Inclisiran has demonstrated promising LDL-C-lowering ability in phase 1 and 2 clinical trials, 
and the on-going ORION program will assess its effect on cardiovascular outcomes in 
approximately 15,000 atherosclerotic CVD patients in a phase 3 trial [29]. Another option is 
ezetimibe, which reduces LDL-C by inhibiting the absorption of cholesterol at the intestinal 
brush border [30]. Clinical studies have reported a 15-22% reduction in LDL-C after ezetimibe 
monotherapy [10] and results from clinical trials [20, 31] also support its use as a co-therapy 
with statins. 
 
Despite some promising outcomes as discussed above, the significant residual risk for CVD in 
statin-treated patients emphasizes the detrimental effects of unresolved, chronic inflammation. 
Whilst statins have considerably decreased CVD-related mortalities over the years, currently-
standard interventions are inadequate for completely combating this residual risk of recurrent 
events in post-MI patients [20, 32, 33], emphasizing the significant role of inflammation 
independent of hyperlipidemia and the need for therapeutic avenues beyond lipoprotein 
homeostasis. Furthermore, the anti-inflammatory actions of statins could be a major contributor 
to its ability to reduce CVD. Indeed, results of the JUPITER trial (Justification for the Use of 
Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin) showed rosuvastatin to 
significantly reduce the incidence of primary cardiovascular events in those with systemic 
inflammation without elevated LDL-C levels (and so would not have qualified for statin 
therapy) [34]. The promising results provided the rationale for further clinical trials 
investigating the efficacy of other anti-inflammatory therapies (discussed later in Section 5). 
Since MI and strokes can also occur in patients without hyperlipidemia [35], the capability of 
ongoing inflammation to negatively-affect patient outcome despite successful lowering of 
LDL-C is highlighted. Importantly, increased levels of high-sensitivity C-reactive protein 
(hsCRP) (a non-specific biomarker of inflammatory status) have been identified in patients on 
statin therapy [36, 37], indicating that the anti-inflammatory actions of statins are inadequate 
for completely combating residual inflammation and subsequent CVD risk in these patients. 
 
4. Inflammation in atherosclerosis 
 
Both pro-inflammatory and anti-inflammatory cytokines have roles in modulating 
cardiovascular health. In atherosclerosis, the former prevail, tipping the balance in favor of 
inflammation rather than its resolution. Cytokines are a large group of proteins subdivided into 
several classes that include interleukins (ILs), chemokines, tumor necrosis factors (TNFs) and 
interferons (IFNs), which orchestrate inflammation and modulate both the innate and adaptive 
immune responses. Pro-inflammatory cytokines are fundamental drivers of atherosclerosis; 
their activities can enhance the inflammatory state, modulate foam cell formation, and 
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influence plaque development and progression through to clinical sequelae arising from its 
rupture [3, 6, 38]. It is therefore unsurprising that cytokines have long been recognized as 
potential therapeutic targets for atherosclerosis. Various pro-inflammatory cytokines are 
expressed in atherosclerotic plaques, and all cell types implicated in the disease are able to 
produce, as well as respond to, these cytokines. However, the exact mechanisms underlying 
how pro-inflammatory cytokines contribute to plaque destabilization remains elusive, although 
it is generally accepted that increasing inflammation positively correlates with risk of plaque 
rupture. Key pro-atherogenic cytokines, such as IL-1β, IFN-γ and TNF-α, are implicated in 
multiple processes that propagate atherosclerotic plaque development, as shown in Figure 1 
and previously dealt with in our reviews [3, 38] (latter published in this journal). Therefore, 
given the fundamental role of inflammation in atherosclerosis, dampening inflammatory 
processes via suppression of pro-inflammatory cytokines may naturally attenuate disease 
progression and reduce plaque burden. Many pre-clinical studies blocking the actions of pro-
atherogenic cytokines, such as IL-1β, most-commonly using neutralizing antibodies (or less-
commonly, using soluble decoy receptors) have highlighted their therapeutic potential. 
 
 4.1 Inflammasome activation 
 
IL-1β is a particularly potent pro-atherogenic cytokine capable of inducing macrophage 
polarization to the M1, pro-inflammatory phenotype, as well as being a major activator of 
innate immunity and capable of inducing self-expression [39, 40]. IL-1β stimulates the 
production of IL-6 (by various cell types) which promotes the synthesis of acute phase reactants 
(e.g. fibrinogen and plasminogen activator inhibitor) and CRP by hepatocytes [41]. CRP is 
hence a marker of elevated inflammation and potentially a better predictor of MACE in 
comparison to LDL-C [42]. Production and release of IL-1β can be stimulated by multiple 
factors. LDL modification and foam cell lysis can stimulate the production of ‘danger signals’ 
which activate pattern recognition receptors, including SRs, toll-like receptors (TLRs) and 
NOD-like receptors (NLRs) by macrophages and other cells of the innate immune system [43]. 
Uptake of cholesterol crystals by macrophages via macropinocytosis and crystallization of 
intracellular cholesterol activates the NLR family, pyrin domain containing 3 (NLRP3) 
inflammasome [44]. This process involves lysosomal destabilization, ROS release and the 
action of the caspase-1 protease, resulting in the cleavage and secretion of potent pro-
inflammatory cytokines, IL-1β and IL-18 [44, 45]. This inflammasome is hence a key driver 
of IL-1β-mediated inflammatory responses and can also be activated by other ‘danger signals’, 
including calcium phosphate crystals and oxLDL within macrophages [45]. Whilst deficiency 
in NLRP3 or caspase-1 failed to inhibit macrophage infiltration and atherosclerosis progression 
[46], deficiency in IL-1β has been found to reduce disease severity [47], and monoclonal 
antibodies targeting IL-1β successfully inhibited plaque formation [48] in apolipoprotein E 
deficient (ApoE-/-) mice. Therefore, these in vivo data support the crucial involvement of IL-
1β, in atherogenesis and disease progression, demonstrating that its suppression attenuates 
plaque development. 
 
5. From bench to bedside: clinical trials exploiting anti-inflammatory therapies 
 
 5.1 The CANTOS trial and CIRT 
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Whilst pre-clinical studies have confirmed the immense potential of targeting 
cytokines/inflammation in atherosclerosis, large clinical trials have only been carried out 
recently. In particular, the outcomes of two randomized, double blind, placebo-controlled 
clinical trials have opened up insights into the application of anti-inflammatory therapies for 
the prevention of atherosclerosis-related events (despite one of these being unsuccessful). 
Results of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial 
found that administration of the human IL-1β monoclonal antibody, canakinumab, to previous 
MI patients with elevated hsCRP, significantly reduced the occurrence of MACE by 17% (at 
150 and 300 mg doses) without lowering plasma cholesterol levels [49] (summarized in Table 
1). In contrast to this, the use of a broad spectrum anti-inflammatory, low-dose methotrexate, 
in the Cardiovascular Inflammation Reduction Trial (CIRT) had no effect on IL-1β, -6 or 
hsCRP and subsequent incidence of cardiovascular events [50] (see Table 1). This is despite 
the association between low-dose methotrexate use and fewer cardiovascular events in arthritic 
patients identified in previous observational studies [51-53]. However, the neutral results from 
the CIRT also echo those obtained from other clinical trials that use other broad-spectrum anti-
inflammatory agents (mentioned later in Section 5.2). 
 
Table 1. Comparison of the two phase 3 clinical trials, CANTOS and CIRT. 
  CANTOS CIRT 




Previous MI and hsCRP level of ≥2 
mg/L 
Previous MI/multivessel coronary 
disease and type 2 
diabetes/metabolic syndrome 
Intervention Canakinumab Low-dose methotrexate 
Dose(s) 
  
50, 150 and 300 mg  
Subcutaneous injection every 3 
months 
Target dose of 15-20 mg weekly 
Biological 
basis 
To target the IL-1β/6 pathway of 
inflammation 
Broad-spectrum anti-inflammatory 
Results 150 and 300 mg reduced hsCRP by 
~35-40% with no significant reduction 
in LDL-C after 48 months 
 
IL-6 was reduced to similar extent 
when measured at 12 months 
No reduction in IL-1β, -6 or hsCRP 
Outcome Significantly lowered rate of recurrent 
cardiovascular events 
No observed benefits 
 
The CANTOS trial was the first large clinical trial to yield positive results with the use of an 
IL-1β neutralizing antibody, which successfully reduced the incidence of secondary MACE 
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compared to placebo. The promising results yielded from this trial not only demonstrate the 
possibility and promise of targeting key cytokines implicated in atherosclerosis to improve 
outcomes, but also provides solid proof of the inflammation hypothesis. However, it is also 
necessary to explore why the CIRT was less successful to better guide the development of anti-
inflammatory strategies in the future. It is important to mention the two key differences in the 
patient cohorts between the two trials; whilst hsCRP levels ≥2 mg/L was a mandatory inclusion 
criterion in the CANTOS trial, this was not the case for the CIRT. Therefore, the lack of effect 
by low-dose methotrexate could be attributed to the absence of elevated (or less severe) 
systemic inflammation due to amplified IL-1β signaling in this patient cohort. This is supported 
by the disparity between the median baseline CRP levels (and IL-6 to a lesser extent) between 
the two patient populations, which were much higher in the CANTOS cohort compared to that 
of the CIRT, and so the CIRT cohort did not necessarily represent residual inflammatory risk 
like that of the CANTOS. Also noteworthy is that although the actions of low-dose 
methotrexate are thought to suppress the actions of proinflammatory cytokines (IL-2, -6 and 
TNF-α), stimulate anti-inflammatory cytokine production, and dampen macrophage activation 
and the T-helper-1 response [54], it has no specific effects on the IL-1β/6 pathway, thereby 
explaining the lack of reduction in hsCRP levels after treatment. Furthermore, perhaps 
implications of co-morbidities, which is common in CVD patients, and other parameters 
affecting cardiovascular health should also be given careful consideration when predicting 
response to treatment. The CIRT cohort consisted of patients with previous MI or multivessel 
coronary disease combined with type 2 diabetes or metabolic syndrome, and a higher 
percentage of patients with hypertension than that of the CANTOS trial, and so other factors 
may have had an impact on treatment success. It would therefore have been interesting to 
directly compare the effect of canakinumab to low-dose methotrexate on previous patients of 
MI with elevated hsCRP levels to verify this and further confirm the effectiveness of targeting 
IL-1β in at-risk patients.  
 
In summary, results of both trials suggest that targeting a specific pro-atherogenic cytokine is 
a more effective approach than targeting inflammation using broad-spectrum agents that 
perhaps have a smaller effect on a number of pro-inflammatory mediators, rather than a 
targeted effect on one. Whilst inflammation has long been accepted to underpin the 
pathophysiology of atherosclerotic disease, the CANTOS trial effectively translated years of 
scientific research into reality, demonstrating that targeted reduction of IL-1β levels 
successfully reduces inflammatory burden and subsequent occurrence of secondary 
cardiovascular events in human patients. Taken together, these data largely support the 
effectiveness of using CRP as a biomarker of inflammation and the potential of targeting the 
IL-1/6 pathway to attenuate residual inflammatory risk in statin-treated patients and the 
incidence of adverse cardiovascular events. In contrast to this, a recent study by Gomez et al. 
[55] using smooth muscle cells (SMC) lineage tracing in ApoE-/- mice found IL-1β to encourage 
plaque stability in late-stage atherosclerosis. Results of this study showed that treatment with 
IL-1β antibody reduced SMC and collagen content, but increased macrophages within the 
fibrous cap, with no change in lesion size itself and full inhibition of beneficial outward 
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remodeling. Therefore, IL-1β may not be solely pro-atherogenic with effects depending on the 
stage of disease, stressing the complex etiology and pathophysiology of atherosclerosis, which 
may, in part at least, be responsible for the clinical challenge of preventing primary and 
secondary MACE.  
 
 5.2 Other trials 
 
Other major large phase 3 clinical trials that exploit anti-inflammatory therapies for 
atherosclerotic disease include the LoDoCo (Low-dose colchicine for secondary prevention of 
CVD) [56], SOLID-TIMI (Effect of darapladib on major coronary events after an acute 
coronary syndrome) [57] and LATITUDE-TIMI (Effect of losmapimod on cardiovascular 
outcomes in patients hospitalized with acute MI) [58] trials. Of these, benefit was only 
observed in the LoDoCo trial, which used colchicine, a broad-spectrum anti-inflammatory 
previously employed to treat inflammatory disorders such as gout and recurrent pericarditis 
[56]. In contrast to low-dose methotrexate, colchicine is an alkaloid whose anti-inflammatory 
properties include antitubulin activity that inhibits neutrophil function [59], which may 
therefore exert its positive, anti-atherogenic effects by inhibiting neutrophilia and subsequent 
neutrophil-mediated secondary infiltration of monocytes into the lesion [60]. In a cohort of 532 
patients with stable coronary disease receiving aspirin and/or clopidogel and statins, treatment 
with 0.5 mg/day of colchicine significantly reduced prevalence of cardiovascular events (4.5%) 
compared to placebo (16.0%) though a small percentage of patients showed intestinal 
intolerance towards colchicine [61]. These promising results suggest a potential for even 
targeting key leukocytes implicated in inflammatory processes that underpin atherosclerosis 
and directly contribute to lesion growth. There are also a number of other clinical trials (mainly 
phase 3) investigating the ability of colchicine to prevent adverse cardiovascular events 
associated with coronary disease (e.g. LoDoCo2 [62], COACS (Colchicine for Acute Coronary 
Syndromes; NCT01906749)) and cerebrovascular disease (e.g. CONVINVE (Colchicine for 
Prevention of Vascular Inflammation in Non-cardio Embolic Stroke; NCT02898610)), with 
more results due soon. Results of the very-recent trial COLCOT (Colchicine Cardiovascular 
Outcomes Trial), involving 4,745 post-MI patients (≤30 days), showed that 0.5 mg/day of 
colchicine significantly reduced the risk of ischemic cardiovascular events compared to 
placebo, with benefits in relation to cardiovascular end points comparable to those of 
canakinumab in the CANTOS trial [61]. In a small patient subgroup (where data were 
available), CRP was reduced by over 65% in the first 6 months post-MI with similar changes 
in leukocyte counts observed in both groups (although not significant) [61]. However, these 
observations should be interpreted with caution due to the small size of the subgroup that was 
not randomly selected from the full cohort and hence offer limited representation. Furthermore, 
a much longer follow-up period with a larger patient cohort and quantitative assessment of 
CVD and inflammation biomarkers is required to ascertain the safety and efficacy of long-term 
colchicine treatment. 
 
Other studies have explored the use of IL-1 receptor antagonist (IL-1ra) therapy on 
cardiovascular outcomes, such as the MRC-ILA Heart Study (Effect of IL-1ra on markers of 
inflammation in non-ST elevation acute coronary syndromes) [63] and the VCU-ART trial 
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(Virginia Commonwealth University Anakinra Remodeling Trial) [64-66]. The MRC-ILA 
study is a phase 2 clinical trial involving 182 patients with non-ST elevation acute coronary 
syndrome (ACS; NSTE-ACS) presenting <48 hours from the onset of chest pain. This study 
investigated the effects of short-term IL-1ra administration on hsCRP levels post-NSTE-ACS, 
since IL-1 drives CRP levels during NSTE-ACS. Daily subcutaneous IL-1ra injection at 100 
mg/day for 14 days significantly lowered hsCRP and IL-6 levels below those of day 1, and 
these were also significantly lower when compared to placebo [63]. There was also significant 
suppression of leukocyte count throughout the treatment (without overt neutropaenia). 
However, there was no significant difference in MACE at 30 days or 3 months between the 
treatment and the placebo groups. This is unsurprising since cessation of IL-1ra treatment was 
associated with an increase in hsCRP and IL-6 levels, suggesting 14 days treatment is 
insufficient for continued suppression or controlling post NSTE-ACS inflammation. However, 
power limitations of this study prevent conclusive analysis of clinical outcomes and so the 
overall effect on IL-1ra treatment on CVD risk cannot be inferred from these results. Further 
studies with larger cohorts over a longer term are required to determine the optimal treatment 
duration, safety and efficacy of IL-1ra for ACS patients.  
 
The VCU-ART [67] and VCU-ART2 [65] similarly investigated the effect of 100 mg/day 
anakinra, a recombinant IL-1ra, for 14 days on adverse cardiac remodeling in post-acute MI 
(AMI) patients. When results of both these studies are combined (N=40), anakinra significantly 
dampened elevations of CRP levels, and hence acute inflammation associated with ST-segment 
elevation AMI (STEMI), during the first 72 hours compared to placebo. However, about half 
of those in the anakinra group experienced an increase in CRP compared to baseline, and 
importantly, CRP levels remained heightened beyond the upper limit of normal, suggesting 
residual cardiovascular risk. This dose of anakinra, or anakinra monotherapy, may hence be 
insufficient to combat the acute and severe inflammation that occurs with STEMI. Re-
evaluation of the dose and duration, as well as combining with another anti-
cytokine/inflammatory therapy may be necessary. Whilst the overall incidence of new heart 
failure was lower in the treatment group with an absolute risk reduction of 25% at 3 months 
follow-up, additional larger clinical trials are required to determine the short and long-term 
safety and efficacy of anakinra treatment for the prevention of adverse cardiac remodeling and 
secondary cardiovascular events. Key limitations include the small sample size, even after 
combining the VCU-ART and VCU-ART2 cohorts, as well as the lack of true baseline 
measurements which restrict assessment of treatment efficacy and accurate quantitation of its 
effect on biomarkers of the IL-1-mediated inflammatory response. Investigators also admit to 
overestimation of the treatment effect on left ventricle remodeling in the first VCU-ART study, 
resulting in too optimistic a sample size in the VCU-ART2, and so neither studies possessed 
sufficient power to detect differences in specific clinical events. These studies suggest anakinra 
has promise for combating the amplified IL-1-mediated inflammatory response in STEMI but 
progression onto a phase 2 clinical trial involving 99 patients (results to be published) [66] will 
provide more solid evidence.  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly and widely used 
anti-inflammatory therapies, but cardiovascular toxicity associated with their use (especially 
high dose, long-term) has been a cause for concern. NSAIDs induce analgesic and anti-
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inflammatory effects via inhibition of cyclooxygenase (COX), which exists in two isoforms; 
COX-1 (constitutively expressed in majority of the cells) and COX-2 (induced by 
proinflammatory stimuli) [68]. Meta-analyses analyzing NSAIDs and coxibs, selective COX-
2 inhibitors (developed to combat gastrointestinal side-effects associated with COX-1 
inhibitors) in 31 [69, 70] and 280 [71] trials have correlated these, especially coxibs, with 
increased risk of adverse cardiovascular events. As the degree of risk appears dose and 
duration-dependent, the use of minimum effective dose and duration, and avoidance in high-
risk CVD patients is hence recommended.  
 
Taken together, the phase 2 and 3 clinical trials detailed above illustrate that specific targeting 
of IL-1 is a promising avenue and vital in controlling inflammation and subsequent residual 
cardiovascular risk. 
 
6. The future of anti-inflammatory therapies 
 
As we enter and progress through the era of streamlined medicine to tailor treatments for 
individual patients, the use of accurate biomarkers is proving increasingly important for 
implementation of more effective treatment strategies. The CANTOS trial also provided 
evidence supporting the use of CRP quantitation to assess inflammatory burden and risk of 
MACE [49]. How best to translate this to medical practice will likely become a  major focus 
of future research; identification of relatively cheap and readily available inhibitors of IL-1β is 
necessary, given the prevalence of atherosclerotic disease and its clinical consequences in 
modern society. Whilst canakinumab has proven effective in combating residual inflammation 
within an at-risk patient cohort, the predominant dilemma is its estimated low cost-
effectiveness, if applied as a standard secondary MACE prevention treatment strategy based 
on current prices [72], which are even greater than that of PCSK9 inhibitors. This will no doubt 
heavily restrict its use as a last resort to the most high-risk patients only after exhaustion of 
other therapeutic options. Therefore, the persisting need for alternative avenues and cheaper 
agents is ever-more essential. 
 
 6.1 Other potential targets for anti-cytokine therapy 
 
Although targeting IL-1β has proven successful in down-regulating inflammation and 
subsequent occurrence of recurrent cardiovascular events, there is still room for improvement 
to further reduce residual inflammatory and cardiovascular risk, warranting exploration of 
other potential target cytokines. Given the promise of targeting the IL-1/6 pathway, it would 
be logical to explore other closely associated cytokines. Production of IL-6 by various cell 
types is stimulated by IL-1β, and so a small amount of IL-1β can induce the generation of a 
large level of IL-6, which in turn induces liver CRP production [73]. Therefore, targeting the 
IL-1/6 pathway further downstream may also elicit similar beneficial effects to inhibiting IL-
1β. In previous in vivo studies, inhibition of IL-6 trans-signaling using soluble glycoprotein 
130 has been shown to attenuate atherosclerosis by inhibiting endothelial dysfunction, VSMC 
infiltration and monocyte recruitment [74]. Increasing IL-6 via injection of the cytokine also 
exacerbated atherosclerotic lesion size [75, 76], and IL-6 lentivirus is capable of inducing 
plaque destabilization [77] in ApoE-/- mice. Surprisingly, IL-6 deficiency in both major animal 
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models of atherosclerosis (ApoE-/- and LDLr-/-) has been shown to promote atherosclerosis [3], 
suggesting pleiotropic effects that may not be strictly pro-atherogenic, perhaps highlighting the 
often-ambiguous roles different cytokines play depending on the microenvironment. Despite 
the same also being true for IL-1β, the reduction in prevalence of secondary MACE, as shown 
by results of the CANTOS trial, suggest that whilst completely removing select pro-
inflammatory cytokines may not positively impact disease progression and may exacerbate it, 
lowering its levels acquires benefit.  
 
IL-18 is another pro-inflammatory cytokine cleaved and secreted by activation of the NLRP3 
inflammasome alongside IL-1β [44] and mediates the actions of IFN-γ, which is capable of 
inducing the activation of pro-inflammatory, M1 macrophages, increasing foam cell formation 
and inducing foam cell apoptosis [38, 78], all processes capable of exacerbating inflammatory 
burden and inciting plaque destabilization. In previous in vivo studies, IL-18 deficiency 
decreased atherosclerosis in ApoE-/- mice, which was associated with reduced IFN-γ activity 
and increased plaque stability [79, 80]. Moreover, IFN-γ deficiency has been found to eliminate 
the detrimental effects of IL-18 on atherosclerosis, and so targeting IFN-γ may inhibit pro-
atherogenic effects of both cytokines. Therefore, these studies have facilitated tremendous 
advancement in our knowledge of the underlying mechanisms of atherosclerosis and along with 
large scale clinical trials, should continue in the quest for alternative therapeutic strategies. 
 
 6.2 Challenges 
 
The CANTOS trial offered the first evidence that targeting a specific pro-inflammatory 
cytokine can successfully prevent recurrent cardiovascular events. The results emphasize not 
only the importance of select pro-inflammatory cytokines in driving disease progression and 
onset of clinical manifestations, but the vitality of comprehensive assessment of patient 
suitability for anti-cytokine therapy, due to the overriding concern of compromising immune 
response and increasing infection risk. Cohorts excluded from the CANTOS trial included 
immunocompromised patients and those suffering from chronic or recurrent infection, 
highlighting the concern of further-diminishing immune function in already-susceptible 
individuals that inevitably accompanies any strategy that targets or manipulates mediators of 
the immune system. Although there was no difference in all-cause mortality, canakinumab was 
in fact associated with a higher incidence of fatal infection (caused by gram positive bacteria) 
compared to placebo [49], and so may need to be restricted to high-risk patients. Additionally, 
in the COLCOT, a higher proportion of patients in the colchicine group experienced diarrhea 
and nausea, with infection and pneumonia also being more common in the colchicine group 
compared to placebo, suggesting a change in immunologic responses [61]. Key issues of 
concern continue to revolve around applying anti-cytokine therapy to immunocompromised 
patients and the conundrum of risk vs benefit. Furthermore, the other smaller, phase 2 trials 
emphasize the need for individualized approaches to match treatment dose and duration with 
inflammation intensity and disease severity [65]. This is especially imperative due to the 
different sources and complexity of proinflammatory signaling contributing to systemic 
inflammation in disease. Moreover, patients with co-morbidities continue to pose a further 
challenge, stressing the ever-persisting need for alternative avenues when standard therapies 
are unsuitable or inadequate. This is where targeted therapies to the atheroma using 
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nanoparticles (NPs), for example, hold such promise, both as a way of minimizing adverse 
systemic side effects and enhancing target specificity. This is since NPs enable explicit control 
of drug activity (both spatial and temporal) and can also provide a more convenient means of 
administration [81]. Convenient and effective therapies with ease of administration may also 
help maintain patient compliance and achieve cost effectiveness. Alternative methods of drug 
delivery such as this are hence pertinent in alleviating, at least in part, pressure on healthcare 
systems, especially when treatment requires regular and continuous administration over a long 
period (which is typical in atherosclerosis). Although there are still limitations and drawbacks 
preventing the use of many NPs in clinical practice [81], many are currently undergoing 
development due to the aforementioned benefits (see [82]).  
 
 6.3 Alternative avenues: nutraceuticals and anti-inflammatory cytokines? 
 
Beyond reducing levels of pro-inflammatory cytokines using monoclonal antibodies, other 
potential avenues include increasing the levels of anti-inflammatory cytokines (using 
recombinant forms) or cells that produce them (e.g. regulatory T cells), and even exploiting 
nutraceuticals to alleviate inflammatory burden. Nutraceuticals, food constituents with health 
benefits beyond nutritional value, represent promising alternative preventative/therapeutic 
avenues that can be combined with current pharmacological therapies for the 
treatment/prevention of CVD [5, 83]. Particular attention has been given to omega-3 
polyunsaturated fatty acids (n-3 PUFAs) [84-86], green tea catechins [87-89] and olive oil 
polyphenols [90-92]. This is mainly due to their identified anti-inflammatory and antioxidant 
activities, with the potential of attenuating atherogenesis and disease progression at a cheaper 
cost in comparison to traditional pharmaceuticals. Recent results obtained from the REDUCE-
IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention) trial showed that 
daily intake of 4 g of icosapent ethyl (a purified eicosapentaenoic acid ethyl ester), by patients 
with established CVD/diabetes/other risk factors on statin therapy, significantly reduced 
incidence of ischemic events [93]. This demonstrates the potential of further inhibiting residual 
risk of MACE via statin and nutraceutical co-therapy. Advancements have also been made in 
the field of omega-6 PUFAs, with an example being dihomo-γ-linolenic acid (DGLA), which 
has demonstrated a range of anti-inflammatory/atherogenic actions in vitro [94], as well as the 
ability to attenuate atherogenesis and disease severity in ApoE-/- mice [95]. Potential anti-
inflammatory cytokines worth mentioning with recent advancements made in knowledge of 
their signal transduction mechanisms are IL-33 [96] and transforming growth factor (TGF)-β 
[97], which are both considered anti-atherogenic. IL-33 can attenuate foam cell formation via 
upregulation of IL-10 expression [98] and TGF-β is released by anti-inflammatory, M2 
macrophages, which possess atheroprotective effects and are associated with plaque regression 
[99]. Importantly, augmenting levels of either cytokine resulted in attenuated disease burden 
presented as smaller lesion size or less abundant foam cells in previous studies using ApoE-/- 
mice [100, 101]. 
   
7. Conclusion 
 
Exciting advancements have been made as we progress into more streamlined therapeutic 
approaches using biomarkers to tailor treatments to individual patients (“personalized 
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medicine”). Successful translation of years of research to medical care is always momentous 
and even more so when the therapy yields success and patient benefit is observed. Whilst 
targeting inflammation has always been recognized as a potential therapeutic strategy for 
systemic conditions such as atherosclerosis, it was not until the last few years that this was 
applied to large clinical trials with successful results. Results of these trials emphasize the 
importance of identifying and characterizing key signaling pathways and the accompanying 
downstream targets implicated in systemic inflammation, which will no doubt fuel future 
research to develop the panel of biomarkers used for better assessment of patient status and 
suitability for treatment. More research focusing on developing cost-effective strategies that 
can be applied abundantly on the front line of medical care and how to mitigate the threat of 
compromising immunity is now required, in order to successfully reduce morbidity and 
mortality associated with atherosclerosis and other chronic inflammatory disorders. 
 
• Future perspective:  
 
We are progressing through an exciting new era of anti-atherogenic therapies, with results 
from recent clinical trials showing the promise and effectiveness of targeting IL-1β for the 
prevention of atherosclerosis-related events [35, 49, 63, 65]. This will no doubt fuel the 
exploration of other potential target cytokines, including IL-6, IL-18 and IFN-γ, which are 
other key pro-atherogenic cytokines closely involved with IL-1β. As the efficacy of anti-
cytokine strategies is verified, focus will shift to identifying and developing novel, cost-
effective agents and more convenient, targeted drug-delivery methods to enable wide-scale 
application of anti-cytokine therapies in front-line medical practice, given the high 
prevalence of atherosclerotic disease. In light of this, repurposing existing agents used to 
treat other systemic inflammatory disorders for the prevention of primary and secondary 
MACE is already being explored. An example of this being colchicine [56, 61, 62], a broad-
spectrum anti-inflammatory that targets neutrophils. A number of phase 3 clinical trials are 
underway with an explosion of data expected upon their completion, guided by promising 
results yielded from the LoDoCo trial [56]. Nutraceuticals is another potential alternative 
avenue, with green tea catechins, olive oil polyphenols and omega-3 PUFAs all having 
anti-inflammatory (and other anti-atherogenic) activities [5, 83]. Promising results of the 
REDUCE-IT trial [93] emphasize the potential of co-therapy with existing pharmacological 
agents. In the next 5 to 10 years, we will likely see an increase in similar clinical trials that 
supplement different anti-inflammatory nutraceuticals as part of currently standard 
treatment strategies to enhance CVD prevention, along with continual development of 
alternative drug-delivery methods to enhance drug target specificity and minimize 
unwanted side effects. 
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• Executive Summary: 
 
Atherosclerosis 
- Atherosclerosis is a chronic inflammatory disorder of the vasculature 
- Accumulation of cholesterol within the arterial wall stimulates infiltration of 
immune cells to the area. 
- Plaque formation and development involves various cell types and chronic 
inflammation. 
- Eventual plaque rupture results in clinical manifestations, including myocardial 
infarction, cerebrovascular accident and peripheral vascular disease, usually as a 
result of thrombosis. 
 
Inflammation in atherosclerosis 
- Pro-inflammatory cytokines and chemokines are implicated in the entirety of the 
disease. 
- In atherosclerosis, the balance of anti- and pro-inflammatory cytokines is tipped in 
favor of the latter, fueling the development of therapies aimed at resolving this 
chronic inflammation in order to improve outcomes. 
- IL-1β is a potent, key pro-atherogenic/inflammatory cytokine whose production can 
be stimulated by multiple factors. 
 
Clinical trials exploiting anti-inflammatory/cytokine therapies 
- Results from the CANTOS trial show that targeting pro-inflammatory cytokine, IL-
1β successfully reduces levels of IL-6 and CRP, lowering incidence of secondary 
cardiovascular events. 
- Whilst the CIRT proved less successful, exploring the reasons behind this is 
important both in knowledge development and to guide future therapies. 
- Another promising anti-cytokine/inflammatory agent is colchicine, which also 
successfully reduced occurrence of secondary events and is currently being 
exploited in a number of other clinical trials with more results due soon. 
Other avenues 
- Targeting other key, pro-inflammatory cytokines such as IL-6, IL-18 and IFN- are 
possibilities worth pursuing. 
- Boosting levels of anti-inflammatory cytokines, such as TGF-β and IL-33, are also 
potential avenues that may dampen inflammation-driven processes. 
- Nutraceuticals may be exploited for their anti-inflammatory effects as a cheaper, 
non-pharmacological alternative. 
- There is a need to identify/develop suitable, cost-effective agents that can achieve 
this and be readily applied to medical practice. 
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• Figure legends: 
 
Figure 1. Inflammation in atherosclerosis. The main pro-atherogenic processes involving 
key cytokines are illustrated. Atherogenesis arises from passage of LDL through the 
endothelium and into the subendothelial space, where its modification, predominantly 
oxidation by ROS and other processes, into oxLDL triggers an immune response, resulting in 
infiltration of immune cells, particularly monocytes and T cells. Cholesterol crystallization 
within macrophages can trigger inflammasome activation, resulting in the production and 
release of potent pro-inflammatory cytokines. Plaque progression is facilitated by enhanced 
inflammation and an increasingly-necrotic phenotype. Plaque destabilization and rupture is 
facilitated by the breakdown of the fibrous cap. See text for more details. Abbreviations: MCP-
1, monocyte chemoattractant/chemotactic protein-1; IL, interleukin; CRP, C-reactive protein; 
IFN, interferon; TNF, tumor necrosis factor; Th-1, T-helper cell; PDGF, platelet-derived 
growth factor. 
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